









Markets
/
Stocks
/
nasdaq-blco
/

Bausch + Lomb Corp

BLCO

15.190USD

-0.190-1.24%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

5.37BMarket Cap

LossP/E TTM



Bausch + Lomb Corp

15.190

-0.190-1.24%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

62 / 207

Overall Ranking

143 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Hold

Current Rating

15.373

Target Price

-0.05%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 27.15% year-on-year.

Fairly Valued

The company’s latest PE is -19.68, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 350.71M shares, decreasing 5.16% quarter-over-quarter.

Held by Carl Icahn

Star Investor Carl Icahn holds 3.50M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.85, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.28B, representing a year-over-year increase of 5.10%, while its net profit experienced a year-over-year increase of 58.94%.

Score

Industry at a Glance

Previous score

6.85

Change



Financials

4.66

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.97

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.74

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.63

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.26

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -19.92, which is -36.03% below the recent high of -12.74 and -3.45% above the recent low of -20.61.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 62/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.77, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Bausch + Lomb Corp is 15.50, with a high of 18.97 and a low of 12.00.

Score

Industry at a Glance

Previous score

6.77

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Hold

Current Rating

15.373

Target Price

-0.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Bausch + Lomb Corp

BLCO

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.93, which is higher than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 15.88 and the support level at 14.56, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.93

Change

-0.39

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.027

Neutral

RSI(14)

56.671

Neutral

STOCH(KDJ)(9,3,3)

53.860

Neutral

ATR(14)

0.421

Low Volatility

CCI(14)

40.308

Neutral

Williams %R

31.646

Buy

TRIX(12,20)

0.283

Sell

StochRSI(14)

46.283

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

15.164

Buy

MA10

15.215

Sell

MA20

14.941

Buy

MA50

14.417

Buy

MA100

13.256

Buy

MA200

14.719

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 99.08%, representing a quarter-over-quarter decrease of 0.04%. The largest institutional shareholder is Carl Icahn, holding a total of 3.50M shares, representing 0.99% of shares outstanding, with 0.52% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bausch Health Companies Inc

310.45M

Icahn Associates Corporation

Star Investors

3.50M

Deutsche Bank Securities Inc.

3.50M

Alberta Investment Management Corporation

3.27M

+8.58%

D. E. Shaw & Co., L.P.

1.88M

-0.33%

GoldenTree Asset Management, LP

2.25M

+29.79%

Whitebox Advisors, L.L.C.

1.62M

+12.46%

Nomura Securities Co., Ltd.

1.26M

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.44, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.63. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.